Recruiting
Phase 4

Novavax & Pfizer-BioNTech

Sponsor:

Henry M. Jackson Foundation for the Advancement of Military Medicine

Code:

NCT07287137

Conditions

COVID -19

COVID - 19

COVID 19

Influenza

Respiratory Virus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Pfizer-BioNTech mRNA COVID-19 vaccine

Novavax recombinant protein vaccine

Study Details

Brief summary:

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Conditions

COVID -19

COVID - 19

COVID 19

Influenza

Respiratory Virus

Study ID

NCT07287137

Start date

Nov 12, 2025

Status verified date

Oct, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria

1. 18-79 years old
2. Have a history of any of the following risk factors for severe COVID:

Current:
  • Age > 65 years old
  • Physical inactivity (defined as <150 mins of moderate activity per week or <75 mins of vigorous activity per week)
  • HIV with CD4 count ≥ 500 cells/ul
  • Smoker
  • Obesity with BMI ≥ 30 and < 40

History of:
  • Asthma
  • Depression or other mood disorder
  • Schizophrenia spectrum disorder
  • Cerebrovascular disease
  • Heart failure
  • Coronary artery disease
  • Cardiomyopathy
  • Pulmonary embolism
  • Pulmonary hypertension
  • Cystic fibrosis
  • Bronchiectasis
  • Chronic obstructive pulmonary disease
  • Interstitial Lung Disease
  • Stage I or II chronic kidney disease (Stage 1 defined as normal GFR (> 90) but with other signs of kidney damage such as proteinuria or hematuria) (Stage 2 defined as having a glomerular filtration rate (GFR) of 60 - 89 ml/min/1.73m2)
  • Gestational diabetes
  • Type 1 diabetes with most recent HgbA1C < 7.5%
  • Type 2 diabetes with most recent HgbA1C < 7.5%
  • Liver disease without cirrhosis and with liver enzyme levels (AST and ALT) no greater than three times the upper limit of normal
  • Smoking
3. Military Health System beneficiary and DEERS eligible
4. Willing to be randomized to receive either the Novavax COVID-19 vaccine or the mRNA Pfizer-BioNTech COVID-19 vaccine
5. Will be able to return for a clinic visit in approximately 30 days, Day 150, and be able to follow-up online for the next 9 months.

Exclusion Criteria

1. History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
2. Received a COVID-19 vaccine in the last 3 months.
3. Tested positive for COVID-19 in the past 3 months.

\- Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit.
4. Active use of immune modulating medications.

\- Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function.
5. Diagnosed with immunocompromised stated.

\- Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen).
6. Diabetes with the most recent HgbA1C ≥ 7.5.
7. Stage III or greater chronic kidney disease

\- Defined as estimated glomerular filtration rate < 60 ml/min/1.73m2)
8. Obesity with a BMI ≥ 40
9. HIV with a CD4 cell count < 500 cells/ul
10. History of solid organ or bone marrow transplant.
11. Active malignancy

\- Defined as any cancer that is currently being treated or has shown evidence of progression within the past year.
12. Chronic liver disease with compensated or decompensated cirrhosis, or liver enzyme levels (AST or ALT) greater than three times the upper limit of normal.

Study Design

Enrollment

54 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

active comparator: For fall of 2026, Arm 1 of the study will be the Pfizer-BioNTech mRNA COVID-19 vac

Arm 1 of the study will be Pfizer-BioNTech mRNA COVID-19 vaccine

active comparator: For fall of 2026, Arm 2 of the study will be the Novavax recombinant protein vaccine

Arm 2 of the study will be the Novavax recombinant protein vaccine

Interventions

Pfizer-BioNTech mRNA COVID-19 vaccine

COVID-19 Vaccine, mRNA

Novavax recombinant protein vaccine

Recombinant protein vaccine

Primary outcome measure

  • Variant-specific immune responses [ Time Frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination, 30 days (+/- 10 days), and 150 days (+/- 10 days) after vaccination. ]

Central Contacts and Locations

Central contacts

Marianne Spevak, BSHS

240-694-2067mspevak@hjf.org

Locations

Walter Reed National Military Medical Center

Recruiting

Bethesda, Maryland, United States, 20814

Contacts

Principal Investigator:

Anuradha Ganesan, MD

More Information

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Last update posted

Oct 28, 2026

Last verified

Oct, 2026

Keywords

  • COVID-19 vaccine
  • Influenza vaccine
  • Respiratory virus vaccine
  • Immunogenicity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-29. This information was provided to ClinicalTrials.gov by Henry M. Jackson Foundation for the Advancement of Military Medicine on 2026-10-28. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.